Method for treating pervasive development disorders

Patent metadata

Field	Value
Publication number	US-9624525-B2
Application number	US-201113313629-A
Country	US
Kind code	B2
Filing date	Dec 7, 2011
Priority date	Dec 17, 1999
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.

First claim

The invention claimed is:

1. A method for determining if an individual having a Pervasive Developmental Disorder (PDD) and a subnormal level of fecal chymotrypsin has improved after administration of a dose of digestive enzymes; the method comprising:
a) making a quantitative pre-administration measurement of a symptom of a PDD and measuring a pre-administration level of fecal chymotrypsin in the individual;
b) administering to the individual a dose of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise a protease, an amylase and a lipase;
c) making a quantitative post-administration measurement of the symptom of the PDD and measuring a post-administration level of fecal chymotrypsin in the individual; and
d) comparing the quantitative post-administration measurement of the symptom of the PDD to a quantitative pre-administration measurement of the symptom of the PDD,
wherein a decrease in the quantitative post-administration measurement of the symptom compared to the quantitative pre-administration of the symptom indicates the PDD has improved.

2. The method of claim 1 , wherein the quantitative, post-administration measurement measures social behavior.

3. The method of claim 1 , wherein the quantitative, post-administration measurement measures imitation.

4. The method of claim 1 , wherein the quantitative, post-administration measurement measures body use.

5. The method of claim 1 wherein the quantitative, post-administration measurement measures object use.

6. The method of claim 1 , wherein the quantitative, post-administration measurement measures adaptation to change.

7. The method of claim 1 wherein the quantitative, post-administration measurement measures visual response.

8. The method of claim 1 , wherein the quantitative, post-administration measurement measures listening response.

9. The method of claim 1 , wherein the quantitative, post-administration measurement measures taste, smell, touch response and use.

10. The method of claim 1 , wherein the quantitative, post-administration measurement measures fear.

11. The method of claim 1 , wherein the quantitative, post-administration measurement measures verbal communication.

12. The method of claim 1 , wherein the quantitative, post-administration measurement measures non-verbal communication.

13. The method of claim 1 , wherein the quantitative, post-administration measurement measures activity level.

14. The method of claim 1 , wherein the measurement is a quantitative measurement of general impression.

15. The method of claim 1 , wherein the quantitative, post-administration measurement is a Childhood Autism Rating Scale measurement.

16. The method of claim 1 , wherein the digestive enzymes comprise a protease that comprises chymotrypsin or trypsin.

17. The method of claim 1 , wherein measuring a pre-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.

18. The method of claim 1 , wherein measuring a post-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.

19. A method for determining if an individual having a Pervasive Developmental Disorder (PDD) and a subnormal level of fecal chymotrypsin has improved after administration of a dose of digestive enzymes; the method comprising:
a) making a quantitative pre-administration measurement of a symptom of a PDD and measuring a pre-administration level of fecal chymotrypsin in the individual;
b) administering to the individual a dose of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise a protease, an amylase and a lipase;
c) making a quantitative post-administration measurement of the symptom of the PDD and measuring a post-administration level of fecal chymotrypsin in the individual; and
d) comparing the quantitative post-administration measurement of the symptom of the PDD to a quantitative pre-administration measurement of the symptom of the PDD,
wherein an improvement in the quantitative post-administration measurement of the symptom compared to the quantitative pre-administration of the symptom indicates that the PDD has improved.

20. The method of claim 19 , wherein the quantitative, post-administration measurement measures social behavior.

21. The method of claim 19 , wherein the quantitative, post-administration measurement measures imitation.

22. The method of claim 19 , wherein the quantitative, post-administration measurement measures visual response.

23. The method of claim 19 , wherein the quantitative, post-administration measurement measures listening response.

24. The method of claim 19 , wherein the quantitative, post-administration measurement measures taste, smell, touch response and use.

25. The method of claim 19 , wherein the quantitative, post-administration measurement is a Childhood Autism Rating Scale measurement.

26. The method of claim 19 , wherein the digestive enzymes comprise a protease that comprises chymotrypsin or trypsin.

27. The method of claim 19 , wherein measuring a pre-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.

28. The method of claim 19 , wherein measuring a post-administration level of fecal chymotrypsin comprises enzyme spectrophotometry.

Assignees

• Fallon Joan M
• Curemark Llc

Inventors

• Fallon Joan M

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C12Q1/37 Primary

  involving peptidase or proteinase · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title

• Y10S435/803

  Physical recovery methods, e.g. chromatography, grinding · CPC title

• A61B5/165

  Evaluating the state of mind, e.g. depression, anxiety · CPC title